A Study of the Immune System of Lung Cancer Patients


About this study

The purpose of this study is to better understand how the immune system, the body's natural defense against infection and harmful cells, is affected by the presence of lung cancer and the treatment of lung cancer.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria      

  • Patients with a pathologically confirmed diagnosis of SCLC or adenocarcinoma NSCLC
  • Patients with a diagnosis of moderate to severe COPD by spirometry
  • Age > 18 years
  • Willing to undergo blood draw


Exclusion Criteria     

  • Known autoimmune disease or on immunomodulatory therapy other than oral steroids
  • Patients who have completed definitive therapy or are ineligible for additional therapy
  • Unable to provide informed consent

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Allan Dietz, Ph.D.

Contact us for the latest status

Contact information:

Cancer Center Clinical Trials Referral Office


More information


Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available


Mayo Clinic Footer